RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men

Journal of Medical Virology

Volumn 79, Issue 10, 2007, Pages 1446-1454

  Gibellini, Davide ^a   Borderi, Marco ^a   De Crignis, Elisa ^a   Cicola, Ronny ^a   Vescini, Fabio ^a   Caudarella, Renata ^a   Chiodo, Francesco ^a   Re, Maria Carla ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HIV 1; OPG; Osteopenia; RANKL; TRAIL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PROTEIN BLOOD LEVEL; VIRUS LOAD;

ADULT; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; DENSITOMETRY, X-RAY; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548280376     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20938     Document Type: Article

References (51)

1. Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jorgensen HR, Abrahamsen B. 2005. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 76:90-97.
2. Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C. 2005. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19:25-33.
3. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC. 2004. Bone mineral density is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402-409.
4. Amorosa V, Tebas P. 2006. Bone disease and HIV infection. Clin Infect Dis 42:108-114.
5. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
6. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. 2003. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917-1923.
7. Campbell DG, Stephenson AJ, Li P, Oakeshott RD. 1996. Human immunodeficiency virus infection of human bone derived cells. Clin Orthop Relat Res 331:291-299.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
9. Fakruddin JM, Laurence J. 2003. HIV envelope gpl20-mediated regulation of osteoclastogensis via receptor activator of nuclear factor kb ligand (RANKL) decretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278:48251-48258.
10. Fakruddin JM, Laurence J. 2004. Interactions among HIV-1, interferon gamma and receptor of activated NF-κB ligand (RANKL): Implications for HIV pathogenesis. Clin Exp Immunol 137:538-545.
11. Fakruddin JM, Laurence J. 2005. HIV-1 Vpr enhances production of receptor of activated NF-κB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150:67-78.
12. Fauci AS. 2003. HIV and AIDS: 20 years of science. Nat Med 9:839-843.
13. Fausto A, Bongiovanni P, Cicconi P, Menicagli L, Ligabo EV, Melzi S, Bini T, Sardanelli F, Cornalba G, Monforte A. 2006. Potential predictive factors of osteoporosis in HIV-positive patients. Bone 38:893-897.
14. Feng X. 2005. Regulatory roles and molecular signalling of TNF family members in osteoclats. Gene 350:1-13.
15. Fiore CE, Pennisi P, Ferro G, Ximenes B, Privitelli L, Mangiafico RA, Santoro F, Parisi N, Lombardo T. 2006. Altered osteoprotegerin/ RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm Metab Res 38:417-422.
16. Gibellini D, Re MC, Ponti C, Maldini C, Celeghini C, Cappellini A, La Placa M, Zauli G. 2001. HIV-1 Tat protects CD4+ Jurkat T lymphoblastoid cells from apoptosis mediated by TNF-related apoptosis-inducing ligand. Cell Immunol 207:89-99.
17. Gibellini D, Re MC, Ponti C, Vitone F, Bon I, Fabbri G, Di Iasio MG, Zauli G. 2005. HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity. J Cell Physiol 203:547-556.
18. Green EA, Flavell RA. 1999. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation. J Exp Med 189:1017-1020.
19. Guang X, Hui-Ling S, Zhi-Song C, LinShuang Z. 2005. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90:5765-5768.
20. Herbeuval JP, Boasso A, Grivel JC, Hardy AW, Anderson SA, Dolan MJ, Chougnet C, Lifson JD, Shearer GM. 2005. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 105:2458-2464.
21. Kanis JA. 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO study group. Osteoporos Int 4:368-381.
22. Kim HR, Kim HY, Lee SH. 2006. Elevated serum levels of soluble receptor activator of nuclear factors-{kappa}B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 45:1197-1200.
23. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. 2001. Osteopenia in HIV-infected patients: Is it the disease or is it the treatment? AIDS 15:807-808.
24. Kobayashi Y, Hashimoto F, Miyamoto H, Kanaoka K, Miyazaki-Kawashita Y, Nakashima T, Shibata M, Kobayashi K, Kato Y, Sakai H. 2000. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J Bone Miner Res 15:1924-1934.
25. Kong YY, Boyle WJ, Penninger JM. 2000. Osteoprotegerin ligand: A regulator of immune response and bone physiology. Immunol Today 21:495-502.
26. Konishi M, Takahashi K, Yoshimoto E, Uno K, Kashara K, Mikasa K. 2005. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 19:1240-1241.
27. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. 2005. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111: 194-213.
28. Landonio S, Quirino T, Bonfanti P, Gabris A, Boccassini L, Gulisano C, Vulpio L, Ricci E, Carrabba M, Vigevani GM. 2004. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother 58:505-508.
29. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs RW Jr. 2004. International Society for clinical densitometry. Official positions of the International Society for clinical densitometry. J Clin Endocrinol Metab 89:3651-3655.
30. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP. 1997. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761-1768.
31. Mackay F, Kalled SL. 2002. TNF ligands and receptors in autoimmunity: An update. Curr Opin Immunol 14:783-790.
32. Mellert W, Kleinschmidt A, Schmidt J, Festl H, Emler S, Roth WK, Erfle V. 1990. Infection of human fibroblast and osteoblast-like cells with HIV-1. AIDS 4:524-527.
33. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. 2000. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463-474.
34. Mondy K, Tebas P. 2003. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 36:S101-105.
35. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, De Marco D, Hoffman M, Tebas P. 2003. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482-490.
36. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. 2004. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle. J Bone Miner Res 19:722-727.
37. Moses A, Nelson J, Bagby G. 1998. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 91:1479-1495.
38. Mylonakis E, Paliou M, Rich JD. 2001. Plasma viral load testing in the management of HIV infection. Am Fam Physician 63:483-490.
39. Nacher M, Serrano S, Gonzalez A, Hernandez A, Marinoso ML, Vilella R, Hinarejos P, Diez A, Aubia J. 2001. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS 15:2239-2243.
40. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K. 1998. RANK is the essential signalling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400.
41. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. 2004. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses 17:513-520.
42. Perfetto SP, McCrary G. 1999. Immunophenotyping and assessment of cell function by three-color flow cytometry of peripheral blood lymphocytes. In: Michael N, Kim JH, editors. HIV protocols. Totowa NJ: Humana Press. pp 397-407.
43. Piliero PJ, Gianoukakis AG. 2002. Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. AIDS 16:1565-1566.
44. Salzman NP, Psallidopoulos M, Prewett A, O'Leary R. 1993. Detection of HIV in bone allografts prepared from AIDS autopsy tissue. Clin Orthop 292:384-390.
45. Schoppet M, Preissner KT, Hofbauer LC. 2002. RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22:549-553.
46. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, Hasson H, Danise A, Guffanti M, Lazzarin A, Rubinacci A. 2005. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 6:145-150.
47. Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K. 1998. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 245:382-387.
48. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. 2001. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145:685-690.
49. Xing L, Boyce BF. 2005. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun 328:709-720.
50. Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC, Pauza CD, Salvato MS. 2003. Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4+ cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol 77:6700-6708.
51. Zauli G, Rimondi E, Nicolin V, Melloni E, Celeghini C, Secchiero P. 2004. TNF-related apoptosis inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. Blood 104:2044-2050.